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CD44 is a facultative cell surface proteoglycan that serves as
the principal cell surface receptor for hyaluronan (HA). Studies
have shown that in addition to participating innumerous signal-
ing pathways, CD44 becomes internalized upon engagement by
ligand and that a portion of its intracellular domain can trans-
locate to the nucleuswhere it is believed to play a functional role
in cell proliferation and survival. However, the mechanisms
whereby fragments of CD44 enter the nucleus have not been
elucidated. Here we show that CD44 interacts with two import
receptors of the importin  superfamily, importin  itself and
transportin. Inhibition of importin -dependent transport
failed to block CD44 accumulation in the nucleus. By contrast,
inhibition of the transportin-dependent pathway abrogated
CD44 import. Mutagenesis of the intracellular domain of CD44
revealed that the 20 membrane-proximal residues contain
sequences required for transportin-mediated nuclear transport.
Our observations provide evidence that CD44 interacts with
importin family members and identify the transportin-depen-
dent pathway as the mechanism whereby full-length CD44
enters the nucleus.
Proteins cross the double membrane of the nuclear envelope
through nuclear pores. To traverse this barrier, proteins larger
than 40 kDa must bind to soluble transport factors or carrier
molecules that shuttle between the cytoplasm and the nucleus
(1).Most of the nuclear transport factors belong to the-karyo-
pherin family and are classified, according to their function, as
importins or exportins (2). In the cytoplasm, cargo proteins
containing a nuclear localization signal (NLS)2 are usually
bound by the adaptor protein importin , followed by the car-
rier importin  (2), although in some cases, importin  binding
is not required (3). Importin-bound cargo is then translocated
through the nuclear pore complex and is released in the nucleus
following binding of importin  to RanGTP protein (2). The
importin-Ran complex is exported to the cytoplasm where it
dissociates upon RanGTP conversion to RanGDP. An analo-
gous mechanism is used by mRNA-binding proteins, where
cargo is recognized by the transportin1 carrier (2). Interest-
ingly, it has also been shown that some proteins, including
-catenin, SMAD, and ERK2, can be imported into the nucleus
without involvement of importins and RanGTP (4).
Nuclear export is analogous to the importmechanism. There
is a single karyopherin protein, Crm1, that upon recognition of
a nuclear export sequence binds the target protein in the
nucleus and upon stimulation by Ran protein releases the
cargo into the cytoplasm (2). The mechanisms described
above are common for cytoplasmic proteins, but there is also
some evidence that the same pathways might be used for
nuclear translocation of the full-length transmembrane
receptors (5, 6).
Growth factor receptor signaling proceeds as a cascade of
intracellular events. Receptor engagement by ligand on the cell
surface typically results in receptor clustering and, depending
on the receptor type, phosphorylation of the intracellular
domain. Recruitment of adaptormolecules ensues and an intra-
cellular signal is generated and relayed by numerous proteins
that constitute the cascade to finally target the gene transcrip-
tionmachinery and alter gene expression. In recent years, how-
ever, numerous reports have shown that transmembrane
receptors themselves can play amore direct role in signal trans-
mission to the nucleus (6).
CD44 is a polymorphic transmembrane glycoprotein that
serves as the principal cell surface receptor for hyaluronan
(HA) and can affect numerous cellular processes, including
cell adhesion, proliferation, and migration. Based on its
diverse functions, CD44 is implicated in a range of physio-
logical and pathological processes including normal devel-
opment, inflammation, and cancer progression (7). Because
it resides in lipid rafts in the cell membrane, CD44 serves not
only as a receptor for extracellular matrix components,
including HA, but as a co-receptor for receptor tyrosine
kinases of the ErbB family (8) and Met (9). CD44 also plays a
role in anchorage of the actin cytoskeleton to the plasma
membrane, which is important for cell motility, and inter-
acts with the ezrin-radixin-moesin family of cytoskeletal
adaptors (10), as well as merlin (11), through which much of
its most relevant signaling for cell motility and survival is
believed to occur. Upon engagement by HA or other ligands,
CD44 is internalized and at least a fraction of the internal-
ized pool is subjected to proteolytic cleavage. It has been
shown that after sequential cleavage, the intracellular
domain (ICD) of CD44 is translocated to the nucleus, where
it is believed to participate in the regulation of gene tran-
scription (12). However, the mechanism of CD44 ICD trans-
port to the nucleus has not been elucidated.
In the present work, we show that the full-length CD44 pro-
tein localizes to the nucleus of several cell types. We also pro-
vide evidence that full-length CD44 nuclear shuttling is
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dependent on transportin1 (TNPO1, karyopherin2) and
exporin Crm1 and that it influences gene transcription.
EXPERIMENTAL PROCEDURES
Cell Culture
The MNNG/HOS sarcoma cell line was cultured in DMEM
with 4.5mg/ml of glucose (Invitrogen), supplementedwith 10%
fetal calf serum (Amimed), 1% non-essential amino acids, and
1% penicillin/streptomycin (10,000 units/10,000 g/ml,
Invitrogen). PC3 (prostate adenocarcinoma), MRC5 (fetal
fibroblasts), andMC (melanoma) cells were cultured inDMEM
with 4.5mg/ml of glucose (Invitrogen), supplementedwith 10%
fetal calf serum and 1% penicillin/streptomycin (Invitrogen).
MCF10A (mammary epithelial) cells were cultured in DMEM/
F-12 supplemented with 2% horse serum, 1% penicillin/strep-
tomycin (Invitrogen), 2 mM L-glutamine, 20 ng/ml of EGF, 100
ng/ml of cholera toxin, 10 g/ml of insulin, and 500 ng/ml of
hydrocortisone.
Plasmid Constructs and Transfection
CD44 mutants were constructed by PCR using the standard
isoform of CD44 as template. For the construction of the CD44





GTGGACTC-3; and R2, 5-CCGCTCGAGCGGCTATTAC-
ACCCCAATCTTCATGTC-3. Both PCR products were
simultaneously ligated into the pMSCV hygro vector (Clon-
tech). For the construction of the CD44 t-60mutant, primer F1
and primer R3, 5-CCGCTCGAGCGGCTACAAATGCACC-
ATTTCCTGAG-3, were used. For the preparation of the
CD44dt mutant primer F1 and R4, 5-CCGCTCGAGCGGCT-
AACTGTTGACTGCAATGCAAAC-3, were used. For the
construction of the CD44dsp mutant primer F3, 5-GAAGA-
TCTTCGCCACCATGCAGATCGATTTGAATATAACC-3,
and R2 were used. The CD44R41A mutant was prepared as
described in Ref. 13. The CD44ICD was constructed with F4,
5-CAGATCTGCCACCATGGCAGTCAACAGTCGAAGA-
3, and R2 primers.
MC cell infection was performed using a virus produced by
GP2 cells transfected with the pMSCV_hygro vector con-
structs. Selection of infected MC cells was done by addition
of 500 g/ml of hygromycin to the culture medium. For over-
expression in COS-7 cells pCDM8-based constructs were
prepared by subcloning CD44 cytoplasmic tail mutants and
amplifying TNPO1 with primers: F5, 5-CGGGATCCCGCC-
ACCATGGTGTGGGACCGGCAAAC-3 and R5, 5-CCCTC-
GAGGGTTAAACACCATAAAAAGCTGCAAGAC-3. Cells
were transfected with FuGENE reagent (Roche) according to
the manufacturer’s protocol.
shRNA specific for CD44 was designed according to earlier
reports (14). The sequences were cloned into the pSiren vector
(Clontech), which was used to transfect the 293 cells. MNNG/
HOS cells were then infected and selected with 1 g/ml of
puromycin.
Immunofluorescence
Antibodies used in immunofluorescence experiments were:
anti-CD44 N-terminal; Brick 223 and Brick 222 (1:100, 1
mg/ml, mouse monoclonal, kindly provided by Frances Spring
from the International Blood Group Reference Laboratory,
Bristol, UK), anti-BrdU (1:300, 0.5 mg/ml, mouse monoclonal,
Pharmingen; 0.1 mg/ml, mouse monoclonal, Roche Applied
Science), and donkey anti-mouse Alexa 488 (1:1300, Molecular
Probes). For detection of the ICD domain, anti-CD44 C-termi-
nal antibody was used (1:200, 0.5 mg/ml, rabbit polyclonal,
Abcam). Specificity of each antibody was compared with the
isotype-matched control antibody.
For immunofluorescence with CD44, cells were fixed with
4% paraformaldehyde, washed, permeabilized with 3% Triton
X-100, stained with each antibody for 30 min, and mounted in
1:1000DAPI inmountingmedium (ThermoShandon). For BrU
(bromouridine) incorporation immunofluorescence anti-BrdU
antibodies from Pharmingen were used (1:300). All images
were acquiredwith Leica SP5AOBS confocalmicroscope at the
Core Imaging Facility of theUniversity of Lausanne. The acqui-
sitionwas performed in sequentialmode to avoid the dye cross-
talk. CD44 localization was analyzed in Z-stacks with Imaris
software. Colocalization percentage was calculated based on
voxel colocalization within an image, normalized to cell num-
ber (Imaris and Image J softwares).
Immunoprecipitation
Immunoprecipitation from the Nuclear Fractions (Modified
from Ref. 15)—Cells were cultured until 85–90% confluence,
then scraped in PBS with protease inhibitors (PI), spun down,
and lysed in a Dounce homogenizer with 3 volumes of the
buffer A (10 mM Hepes, pH 7.9, 15 mM MgCl2, 10 mM KCl,
freshly added PI and 1 mMDTT). The number of strokes of the
homogenizer was determined by checking the cell lysis under a
light microscope. The lysate was then centrifuged at 3,500 g
for 5 min at 4 °C and the nuclear pellet was resuspended in 3
volumes of buffer C (20 mM Hepes, pH 7.9, 25% (v/v) glycerol,
420 mM KCl, 1.5 mMMgCl2, 0.2 EDTA, freshly added PI, and 1
mM DTT). Nuclei were lysed for 30 min to 1 h on ice and the
lysates were ultracentrifuged at 24,000  g for 20 min at 4 °C.
Nuclear supernatants were then collected and diluted 10 times
with buffer D (20 mM Hepes, pH 7.9, 20% (v/v) glycerol, 0.2
EDTA, 0.2% Triton X-100, freshly added PI). To eliminate the
precipitate, the sample was spun at 16,000  g for 10 min at
4 °C. Preclearingwith agarose-proteinA beads (GEHealthcare)
was then performed (the beads were previously washed with
buffer D with 150 mM KCl). Next, the beads were spun down,
discarded, and antibodies were added to the nuclear extract.
Incubation with the antibodies was performed overnight at
4 °C. A fresh batch of pre-washed beads was then added to the
extracts and incubated for 2–12 h at 4 °C. The beads were then
spun down and washed 10 times with buffer D with 300 mM
KCl. Finally, the beads were resuspended in reducing sample
buffer and boiled for 15 min. The released proteins were ana-
lyzed by SDS-PAGE and Western blotting. For each precipita-
tion experiment the nuclear extracts were divided into two
Nuclear Import of CD44 by Transportin
OCTOBER 1, 2010•VOLUME 285•NUMBER 40 JOURNAL OF BIOLOGICAL CHEMISTRY 30549
equal fractions, one of which was incubated with the unrelated,
isotype-matched antibody to provide the control.
Immunoprecipitation for the Cytoplasmic Fraction—Cells
were cultured until 85–90% confluence was reached, then
scraped in PBS with protein inhibitors, spun down, and resus-
pended in 3 volumes of the modified RIPA lysis buffer (50 mM
Tris-HCl, pH 7.4, 1%Triton X-100, 150mMNaCl, 1mMEDTA,
PI). Lysis was performed for 30 min on ice, and the lysate was
centrifuged at 3,500  g for 5 min at 4 °C. Agarose-protein A
beads (previously washed with PBS) were added to the super-
natants and discarded after 1 h of pre-clearing. Incubation with
antibodies was preformed overnight at 4 °C, and incubation
with the beads for 2 h. The beads were then washed 10 times
with PBS, resuspended in sample buffer, and boiled for 15 min.
The released proteins were analyzed by SDS-PAGE and West-
ern blotting. Antibodies used in immunoprecipitation were
anti-CD44 Brick 235 (kindly provided by Frances Spring), anti-
transportin1 (mouse monoclonal, Abcam), mouse IgG2b (BD
Pharmingen), mouse IgG1 (Sigma), and anti-importin (rabbit
polyclonal, Abcam).
Western Blotting
Antibodies used inWestern blotting were anti-CD44 KZ1 (1
g/ml (16)), anti-importin  (rabbit polyclonal, Abcam), anti-
transportin1 (mouse monoclonal, Abcam), exportin Crm1
(rabbit polyclonal, Abcam).
Biotinylation
MNNG/HOS cells were washed with cold PBS containing 1
mM Ca2 and 1 mM Mg2. Biotinylation was performed for 15
min at 4 °C with 500 ng/ml of biotin in PBS containing 1 mM
Ca2 and 1 mM Mg2. Cells were then cultured in normal
medium for 8 h, washed with PBS, scraped, and mechanically
disrupted for immunoprecipitation.
Brefeldin A and Nocodazole Treatment
MNNG/HOS cells cultured on coverslips were incubated
for 1 h with 5g/ml of brefeldin A (Sigma) or for 8 h with 100
ng/ml of nocodazole (Sigma). Cells were then fixed and
stained for immunofluorescence.
Nuclear Import Assay (Modified from Refs. 3 and 17)
Cytosol Preparation for the Nuclear Import Assay—Cells
were scraped and washed twice with cold PBS, then with wash-
ing buffer (10 mM Hepes, pH 7.3, 110 mM KOAc, 2 mM
Mg[OAc]2, 2 mM DTT) and resuspended in 1.5 volume of lysis
buffer (5 mM Hepes, pH 7.3, 10 mM KOAc, 2 mM Mg[OAc]2, 2
mM DTT, 20 M cytochalasin B, freshly added protein inhibi-
tors) and incubated on ice for 10min. Lysis was performedwith
aDounce homogenizer, and cell disruptionwas verified under a
lightmicroscope. Lysates were then subjected to centrifugation
at 15,000 g for 20min, and at 100,000 g for another 30min.
Cytosolic fractions were dialyzed overnight against the trans-
port buffer (20 mM Hepes, pH 7.3, 110 mM KOAc, 5 mM
NaOAc, 2 mM Mg[OAc]2, 1 mM EGTA, 2 mM DTT, PI) and
stored at80 °C.
Importin Depletion—To deplete importin  from the cyto-
plasmic fraction the protocol for immunoprecipitation was
used. The supernatant remaining after the immunoprecipita-
tion was then dialyzed against the transport buffer. Antibodies
used in this assay were anti-importin  (rabbit polyclonal,
Abcam) and rabbit IgG (Sigma).
Nuclear Import Assay—Cells grown on coverslips were
washed with ice-cold transport buffer, permeabilized with 40
g/ml of digitonin (Calbiochem) in ice-cold transport buffer
for 5 min at room temperature, and washed with transport
buffer. Coverslips were then blotted using 50 l of complete
transportmixture, containing 75% cytosol in transport buffer, 1
mM ATP, 5 mM creatine phosphate, 20 units/ml of creatine
phosphokinase, and incubated at 30 °C for 6 h. Cells were then
washed and stained. To block the nuclear transport, wheat
germ agglutinin (Sigma) was added to the transport mixture to
a final concentration of 0.1 mg/ml (18).
Leptomycin B Treatment—Cells were cultured on coverslips
until 85% confluence. Leptomycin B (Sigma) was added to a
final concentration of 20 ng/ml (19) and incubation was con-
ducted for 2, 4, or 20 h at 37 °C. Cells were then prepared for
immunofluorescence.
BrU Incorporation Assay (Modified from Ref. 20)
BrU Incorporation Immunofluorescence—Cells were cul-
tured on coverslips until 85% confluence and incubated with 2
mMbromouridine (Sigma) for 3 h at 37 °C. Cells were then fixed
in ice-cold methanol and incubated with anti-BrdU antibody
(mouse monoclonal, Pharmingen; or mouse monoclonal,
Roche Applied Science) and secondary goat anti-mouse Alexa
488 antibody (Molecular Probes).
BrU Incorporation Multiwell Test—Cells cultured in a
96-well plate were incubated for 3 h with 2 mM BrU, fixed with
ice-cold methanol, and incubated with anti-BrdU antibody
(mouse monoclonal, Pharmingen). The cells were then incu-
batedwith secondary antibody, washed, and incubatedwith the
substrate according to the Cell Proliferation ELISA BrdU col-
orimetric assay (Roche Applied Science).
Mouse Fibroblast Isolation—Pups of B6 or B6/J129 CD44KO
mice were euthanized and rinsed in Betadine and PBS. After
removal of the limbs, the skinwas peeled off, flattened on a Petri
dish and dried for about 30 min. Trypsinization was performed
overnight at 4 °C with 0.25% trypsin (Sigma) in PBS with anti-
biotic/antimycotic (1:100, Invitrogen). Next, the epidermis was
peeled off and the dermis was incubated for 1 h at 37 °C in 0.33
mg/ml of collagenase II and IV (Sigma) with 250 g/ml of glu-
cose (Sigma). The sample was then filtered and cells were spun
down, resuspended, and plated at 2 106 cells/dish in DMEM
with 10% FCS, antibiotic/antimycotic.
Statistical Methods—p values were established by Student’s t
test with equal sample size and unpaired equal variances. The
error bars on the graphs represent S.D. The variances were
analyzed with the analysis of variance test.
RESULTS
Nuclear Localization of CD44—It has been shown that the
intracellular domain of CD44 can be translocated to the
nucleus (12) and that engagement ofHA triggers endocytosis of
the mature CD44 protein (8, 21). To address the intracellular
fate of CD44, we used MNNG/HOS osteosarcoma cells that
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constitutively express high levels of the standard 85–90-kDa
CD44 isoform (CD44H). Immunofluorescence microscopy of
MNNG/HOS cells using an antibody to the extracellular
domain of CD44 revealed the presence of epitopes recognized
by the antibody in the cellmembrane, cytoplasm, but also in the
nucleus (Fig. 1A). Staining of different cell lines, including
MNNG/HOS, the immortalized fibroblast MRC5, and breast
epithelial MCF10A, cell lines, and the prostate carcinoma cell
line PC3,with anti-CD44 antibody revealed that the presence of
the extracellular domain of CD44 in the nucleus was a common
feature, irrespective of cell type. Those results were confirmed
with another anti-CD44 antibody (data not shown).
To ensure that nuclear localization that we observed was due
to translocation of the full-length receptor and not just an
extracellular fragment, we performed immunoprecipitation of
CD44 from the nuclear fraction ofMNNG/HOS cells.Western
blot analysis of the nuclear fraction using anti-CD44 antibody
confirmed the presence of an 85–90-kDa CD44 species that
corresponds to full-length CD44H in the nucleus of MNNG/
HOS cells (Fig. 1B).
MembraneOrigin ofNuclearCD44—Toconfirm the findings
of Lee et al. (22), who showed that nuclear full-length CD44
originates from the cell membrane, we determined whether
biotinylated CD44 could be immunoprecipitated from the
nuclear fraction of MNNG/HOS cells (Fig. 2A). The potential
involvement of the Golgi apparatus and endocytic pathway
were assessed by fluorescent antibody staining of CD44 in cells
treated with brefeldin A or nocodazole, respectively (Fig. 2B).
Confocal microscopy revealed that
CD44 colocalization with DAPI,
which is a hallmark of nuclear local-
ization, decreased after nocodazol
treatment. This result supports the
role of endocytic trafficking in
nuclear transport of CD44.
Previous work (22) has shown
that ligation of cell surface CD44
by antibody or osteopontin can
enhance its nuclear translocation.
We therefore asked whether hyal-
uronic acid binding could play the
same role in vivo. To answer this
question we used the CD44 R41A
mutant, which is unable to bind HA
(13), the dsp mutant lacking the sig-
nal peptide (amino acids 1–20), and
the intracellular domain of CD44
alone (ICD, starting with A669)
(12). pMSCVhygro plasmids con-
taining mutant CD44 were ex-
pressed in human melanoma MC
cells, which have negligible levels of
endogenous HA receptor (Fig. 2C).
We then performed immunofluo-
rescence monitoring of the nuclear
localization of CD44 by assessing its
colocalization with DAPI (Fig. 2D).
We observed that the HA-binding
mutant is transported to the nucleus as efficiently as the full-
length protein. However, deletion of the signal peptide that
results in a mutant that cannot be incorporated into the cell
membrane significantly impaired nuclear localization. The
above results are therefore consistent with previous findings
and show that membrane localization of CD44 is necessary for
its nuclear translocation via the endosomal pathway.
CD44 Interacts with Proteins from the Importin/Exportin
Family—CD44 has been suggested to mediate signal transduc-
tion and to participate in the modulation of numerous cell sig-
naling pathways (7). However, the mechanisms whereby the
HA receptor regulates cell function and behavior remain to be
fully elucidated. To provide insight into CD44 protein-protein
interactions that might be relevant to CD44 transport and
intracellular signaling, we performed a pull-down assay, a large
scale immunoprecipitation followed by a mass spectrometric
analysis, from MNNG/HOS cell lysates using anti-CD44 anti-
body. Mass spectrometric analysis revealed that the full-length
CD44 protein present in the cytoplasmic fraction of MNNG/
HOS cells co-precipitates with several karyopherins that
mediate nuclear-cytoplasmic shuttling (Fig. 3A). Immuno-
precipitation andWestern blot analysis confirmed the inter-
action of CD44 with importin ,transportin 1, and exportin
Crm1 (Fig. 3B).
Nuclear Import of CD44 Is Transportin1-dependent—After
confirming the interaction of CD44 with importin  and trans-
portin1, we assessed the relevance of the two proteins to
nuclear import of the HA receptor by performing a series of
FIGURE 1.Nuclear localization of CD44. A, immunofluorescence staining of CD44 in the indicated cell types;
nuclei stainedwithDAPI; B, immunoprecipitationof CD44 from thenuclear fractionofMNNG/HOS cells; immu-
noprecipitationwas performedwith anti-CD44 Brick 235mAb, and theWestern blot with anti-CD44 KZ1mAb.
C, cytosolic fraction; N, nuclear fraction; IP, fraction immunoprecipitated with anti-CD44 mAb; ISO, fraction
immunoprecipitated with unrelated isotype-matched immunoglobulin.
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nuclear transport assays, as described previously (17). Briefly,
MNNG/HOS cells cultured on coverslips were permeabilized
with digitonin and incubated with cytosol in the presence or
absence of transport inhibitors or with cytosol depleted of
importin. After 6 h of incubation at 30 °C, the cells were fixed,
stained, and examined by immunofluorescence microscopy.
Localization of CD44 was assessed by confocal microscopy and
a colocalization channel for CD44 and DAPI was built. Impor-
tin  depletion from the cytosolic fraction was not sufficient to
inhibit CD44 import to the nucleus (Fig. 4A). However, when
M9M-MBP, a specific inhibitor of transportin1 (kindly pro-
vided by Dr. Zi Chao Zhang) (23), was added to the cytosol,
CD44 import was impaired to the same degree as when wheat
germ agglutinin, a blocker of nuclear pores (18), was used.
Quantification of the colocalization of CD44 andDAPI showed
a nearly 75% decrease of nuclear CD44 in the presence ofM9M
peptide (Fig. 4A), supporting the notion that transportin1 is
required for nuclear import of CD44.
CD44 Is Exported by Exportin CRM1—In the exportin family
of proteins the one with the broadest spectrum of cargo pro-
teins is exportinCrm1 (2). The possible involvement ofCrm1 in
nuclear export of CD44 was therefore tested. Leptomycin B, an
inhibitor of Crm1, was added toMNNG/HOS cells cultured on
coverslips and after 2, 4, and 20 h, localization of CD44 was
assessed by immunofluorescence. Strong nuclear accumulation
of the HA receptor after 4 h of leptomycin treatment was
observed (Fig. 4B), supporting the notion that CD44 shuttles
between the cytoplasm and nucleus.
The First 20 Residues of the Cytoplasmic Tail Contain
Sequences Necessary for Nuclear Translocation of CD44—Be-
cause bothmatureCD44 and its intracellular domain can trans-
locate to the nucleus, we assumed that CD44 sequences that
constitute the NLS are located within its cytoplasmic domain.
To identify the putative CD44 NLS, we constructed three
mutants, each lacking a portion of the cytoplasmic domain (Fig.
5A). pMSCVhygro plasmids containing mutant CD44 were
expressed in human melanoma MC cells, which lack constitu-
tive HA receptor expression (24).We expected that themutant
lacking the first 20 residues of the cytoplasmic domain would
display impaired import to the nucleus based on the similarity
between the 20-amino acid sequence and the predicted trans-
portin1 recognition sequence (Fig. 5B) (25). Protein expression
of the CD44 mutants was assessed by fluorescence-activated
cell sorting (FACS) (Fig. 5C), and revealed only small variations
FIGURE 2. Cell membrane origin of nuclear CD44. A, CD44 immunoprecipitation from the nuclear fraction of surface-biotinylated MNNG/HOS cells. C, cyto-
solic fraction; N, nuclear fraction; IP, fraction immunoprecipitated with anti-CD44 mAb; ISO, fraction immunoprecipitated with unrelated isotype-matched
immunoglobulin; PB, post-immunoprecipitation fractions. B, inhibition of microtubule-dependent endocytosis impairs nuclear localization of CD44. BFA,
brefeldin A. C, overexpression of CD44mutants, real-time PCRwith F4 and R2 primers.D, nuclear localization of CD44mutants. B andD, nuclear localization of
CD44 was observed upon its colocalization with DAPI and measured with Imaris software. Means of at least 5 confocal images are shown.
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in fluorescence intensity amongMC cells expressing the differ-
ent mutants.
Confocal microscopy revealed clear differences in nuclear
localization of mutant CD44, shown here as the colocalization
between CD44 and DAPI staining (Fig. 5C). Mutants lacking
the putative transportin1 recognition sequence displayed
strongly reduced nuclear localization, whereas their cell surface
expression level was comparable with that of WT CD44 (Fig.
5C). These observations are consistent with the involvement of
transportin1 in nuclear import of CD44.
Transportin1 Binding to the Cytoplasmic Tail of CD44—To
assess the binding of transportin1 to the CD44 cytoplasmic
domainmutants, we subcloned the constructs into the pCDM8
vector and co-expressed the CD44 mutants and transportin in
COS7 cells. Immunoprecipitation of the CD44 mutants from
the cytosolic fraction was performed and the presence of
TNPO1was assessed byWestern blotting (Fig. 5D). Deletion of
the cytosolic domain (dt mutant) disrupted the interaction
between CD44 and TNPO1. However, the CD44 mutant lack-
ing the first 20 amino acids of the cytoplasmic domain could
still bind transportin, even though the major portion of the
transportin recognition sequence was missing (Fig. 5,A and B).
This observation shows that removal of the first 20 residues
of the cytoplasmic domain is not sufficient to abrogate binding
of TNPO1 to CD44, but as we have shown above, the observed
residual binding is insufficient for nuclear translocation of the
mutant.
Nuclear CD44 Influences RNA Polymerization—In searching
for the potential function of CD44 in the nucleus we tested
its effect on RNA polymerization. Incorporation of BrU into
nascent RNA reflects the tran-
scriptional activity of cells and can
be readily measured by immu-
nofluorescence or colorimetric
assays. For the purpose of this
assay, MNNG/HOS cells were sta-
bly transfected with pSiren vector
containing CD44 shRNA (14).
Although the knock-down was
efficient with both shRNA se-
quences (Fig. 6A), sequence 1 was
chosen for further experiments.
MNNG/HOS expressing CD44
shRNA or control sequence were
then incubated for 3 h with BrU and
stained with anti-bromodeoxyuri-
dine antibody. Analysis by immuno-
fluorescence microscopy indicated
a decrease of BrU incorporation
close to 60% in knock-down cells
(Fig. 6B). The same result was
obtained with the colorimetric BrU
incorporation assay (based on Cell
Proliferation ELISA BrdU kit,
Roche) (Fig. 6C). An analogous
experiment was performed on
fibroblasts from CD44-deficient
mice. BrU incorporation was de-
creased in cells lacking HA receptor expression in comparison
to wild-type cells (Fig. 6D).
Because these observations suggest the implication of CD44
in RNA polymerization, we asked whether the polymerization
is linked to the presence of full-length CD44 protein in the
nucleus.We therefore performed a BrU incorporation assay on
MC cells expressing CD44 extracellular or cytoplasmic domain
mutants (Fig. 6,E and F).MCcells showed increased BrU incor-
poration when expressing wild-type CD44 compared with the
empty vector, whereas CD44 with impaired nuclear localiza-
tion (dsp, t-20, dt mutants) was not able to induce the same
effect. These results demonstrate that nuclear localization of
CD44 influences RNA polymerization, and is hence involved in
the regulation of gene transcription. Interestingly, it seems that
the HA-binding domain is partially responsible for this effect,
as the R41A mutant failed to increase BrU incorporation even
though it localized to the nucleus (Fig. 2D). Expression of the
ICDof CD44 alonewas sufficient to raise the level of BrU incor-
poration to that attained as a result of full-length receptor
expression. It is conceivable that conformational changes in the
intracellular domain of the R41A mutant impair its influence
on RNA polymerization. These results demonstrate that
nuclear localization of CD44 influences RNA polymerization,
and is hence involved in the regulation of gene transcription.
DISCUSSION
In this work we have uncovered the mechanism whereby
CD44, a transmembrane extracellular matrix receptor protein,
translocates to the nucleus. Previously, the cytoplasmic domain
of CD44 had been detected in the nucleus (12), but the possi-
FIGURE 3. CD44 interacts with karyopherins. A, CD44 interactors identified in the pulldown assay belong to
importin/exportin family of proteins. B, immunoprecipitation (IP) andWestern blot (WB) analysis confirmCD44
interaction with importin , transportin, and exportin. ISO, unrelated isotype-matched immunoglobulin.
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FIGURE 4.Nuclear translocation of CD44 depends on transportin1 and exportin Crm1 but not on importin. A, nuclear import assay; nuclear CD44
wasmonitored according to its colocalization with DAPI staining; importin depletion has no effect on CD44 nuclear localization; transportin1 inhibitor
M9M peptide fused to maltose-binding protein (MBP) has the same effect as the nulcear pore blocker wheat germ agglutinin (WGA) (p values 0. 005);
the effect is quantified by Imaris software as the percentage of colocalization in the region of interest (ROI); 250–300 cells analyzed per condition.
B, leptomycin B (LMB) treatment for 2, 4, and 20 h; 4 h incubation with LMB triggers nuclear accumulation of CD44. All the experiments have been done
in triplicate.
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bility that the full-length HA receptor might also be present in
the nucleus hadnot been ruled out. Recently, Lee et al. (22) have
shown nuclear localization of the full-length CD44 in the
H1299 gastric cancer cell line. We performed immunofluores-
cent staining of theHA receptor in several cell types, noting the
presence of full-length CD44 in the nuclei. In the human
MNNG/HOS osteosarcoma cell line this localization was con-
firmed by immunoprecipitation of the receptor from the
nuclear fraction. In their work, Lee et al. (22) postulated the
internalization of CD44 via the endosomal sorting as the path-
way responsible for the nuclear trafficking of the receptor. Our
results are consistent with this notion, as we were able to pre-
cipitate a biotinylated CD44 from the nuclear fraction of the
MNNG/HOS cells and as blocking of the endocytosis, but not
the Golgi apparatus, was sufficient to inhibit nuclear localiza-
tion of the receptor. We also show that mutant CD44, lacking
the signal peptide required for membrane localization, has a
diminished ability to localize to the nucleus. Ligation of CD44
by osteopontin or Hermes-3 antibody promotes its nuclear
localization (22). We show here that hyaluronic acid binding
does not influence nuclear localization, as nuclear import of the
R41A mutant is not impaired.
The mechanism of CD44 import into the nucleus had until
now not been resolved. Our pulldown assays of CD44 revealed
that its intracellular interactors are predominantly members of
the karyopherin family consistent with the notion that CD44
may shuttle between the cytoplasm and nucleus. Interactions
between CD44 and transportin1, importin , and exportin
Crm1 were confirmed by co-immunoprecipitation experi-
ments. Functional studies using a combination of CD44
mutagenesis and selective transport inhibitors revealed that
transportinmay be the key player in nuclear transport of CD44.
Selective inhibitors of nuclear shuttling pathways, including the
M9M peptide, which is an inhibitor of transportin1 (23), are
FIGURE 5. CD44 contains a transportin1-specific NLS. A, construction of CD44 cytoplasmic tail mutants. B, predicted sequence of transportin1 recognized
NLS (upper line) (23) corresponds to sequences deleted in CD44t-20mutant (lower line). C, CD44 tail mutant expression (right panel) and localization (left panel)
in MC melanoma cells; nuclear CD44 localization in MC cells is presented as colocalization channel of CD44 immunofluorescent staining with DAPI. FACS
analysis shows similar levels of expression of all CD44 constructs in MC cells. D, co-immunoprecipitation of transportin1 with CD44 cytoplasmic tail mutants.
COS7 cells overexpressing TNPO1 together with one of the CD44 tail mutants were subjected to CD44 immunoprecipitationwith Brick 235mAb, andWestern
blot (WB) analysis revealed the presence of transportin in immunoprecipitated fractions. Input controls and isotype-matched controls have been done (data
not shown).
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valuable tools for the study of nuclear import and export. The
sequence of the M9M peptide corresponds to the predicted
NLS recognized by transportin1. Thus M9M is a competitive
inhibitor of cargoes shuttled by transportin1. Nuclear localiza-
tion of CD44 was drastically decreased when theM9M peptide
was added to the transport mixture. The same effect was
observed upon treatment with wheat germ agglutinin, a com-
pound that blocks the nuclear pores and disables molecule
exchange between the nucleus and cytoplasm. Conversely,
depletion of another CD44-interacting import protein, impor-
tin , from the transport machinery did not cause impairment
of CD44 nuclear localization. Taken together, these results are
consistent with a functional interaction between CD44 and
transportin1. Furthermore, the intracellular domain of CD44
contains a sequence that bears homology to a predicted NLS
recognized by transportin1 (25). Mutant CD44 protein, which
lacks the 20-aa fragment, was no longer found in the nucleus.
Interestingly, deletion of the Arg673–Glu692 was not sufficient
to prevent binding of transportin1 to themutant CD44. Crystal
structures of TNPO1 with its several cargo proteins reveal that
the NLS of the protein contains two sites that are responsible
for the interaction (26). SiteA, at the
C-terminal end of the NLS, is the
primary, high affinity binding site.
The localization of this site corre-
sponds to residues DRKPS, which
belong to the predicted NLS, but
were not deleted in our CD44t-20
mutant. TNPO1 binding at site B,
localized at the N terminus of the
NLS, is important for conforma-
tional changes in transportin1 and
for dissociation of the cargo protein
in the nucleus (26). Our results show
that site A binding is sufficient for
interactionofCD44withTNPO1,but
the functional nuclear import of
CD44 cannot occur without the first
membrane-proximal 20 amino acids
of the cytoplasmic tail, which contain
TNPO1 binding site B.
This observation supports the
notion that transportin1 is respon-
sible for nuclear import of CD44.
The fact that CD44 binds several pro-
teins from the importin family, but
that only one of them is sufficient for
nuclear translocation is not surpris-
ing. It has been shown that the tran-
scription factor c-Fos binds several
importins, including importin  and
transportin1 (27). Detailed analysis
showed that transportin1 plays the
key role in the import of c-Fos.
In the present workwe also inves-
tigated the nuclear export of CD44.
The majority of transcription fac-
tors are exported from the nucleus
by exportin Crm1 (2). Interaction between CD44 and exportin
Crm1was confirmed by co-immunoprecipitation. To study the
involvement of Crm1 in the export of nuclear proteins lepto-
mycin B, a selective inhibitor of this exportin, was used (2, 19).
Incubation of the cells with leptomycin B resulted in accumu-
lation of nuclear CD44, thus providing support for the function
of Crm1 in CD44 export.
It has been previously shown that the intracellular domain of
CD44 regulates transcription through CBP/p300 responsive
elements (12). Upon the discovery of the full-length CD44 in
the nucleuswe also speculated that it could take part in the gene
expression process. To target this question we performed BrU
incorporation assays. Bromouridine is taken up by the cells, and
after phosphorylation it is incorporated in the nascent RNA
(20). BrU incorporation can be detected with anti-BrdU anti-
bodies and the amount of labeling reflects the RNA synthesis
levels in the cell. Decreased BrU incorporation was observed in
human MNNG/HOS cells depleted of CD44 and in mouse
fibroblasts derived from HA-receptor knock-out animals. The
decrease in RNA polymerization appears to depend on nuclear
localization of CD44. It was true for cells expressing themutant
FIGURE 6.Nuclear CD44 enhances RNA synthesis. A, shRNA down-regulation of CD44 expression. Immuno-
fluorescence (B) and a colorimetric assay (C) show weaker BrU incorporation in cells depleted of CD44 com-
pared with control cells (mean of three experiments, p value: *0.05). D, a similar effect is observed in colori-
metric assays with CD44/mouse fibroblasts compared with the wild-type cells (mean of three experiments, p
value: * 0.05). E, MC CD44 t-20 mutant incorporates less BrU that the wild type and the CD44 t-60 mutant as
assessed by the colorimetric assay (mean of three experiments, t test comparison of mutants to WT, p values:
*0.05; analysis of variancep value is 0.005593). F, the role of the extracellular domain inBrU incorporation. Lackof
the signal peptide (dsp) or theR41Ahyaluronan-binding sitemutationdecreasesBrU incorporation (representative
experiment, t test comparison ofmutants toWT, p values: *0.05; analysis of variance p value is 0.025).
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lacking the signal peptide that cannot follow the membrane-
endosome-nucleus pathway, as well as for cells expressing the
mutant lacking the NLS recognized by transportin1. Interest-
ingly, the R41Amutation, which disables hyaluronic acid bind-
ing, also decreased incorporation of BrU. To determine,
whether HA bound to CD44 at the cell membrane and
imported into the nucleus or whether the R41Amutant is caus-
ing a conformational change that impairs the protein machin-
ery responsible for RNA polymerization will require further
studies. The experiments based on overexpression of the ICD
domain alone allow us to speculate that it is the domain respon-
sible for recruiting the nuclear proteins that induce RNA
polymerization. Interestingly, in MNNG/HOS cells we did not
find significant amounts of nuclear ICD. Attempts to induce
cleavage of CD44 with 12-O-tetradecanoylphorbol-13-acetate
were also not successful (supplemental Fig. S1). This could
mean that in some cell types, where cleavage of the intracellular
domain of CD44 is not efficient, nuclear translocation of full-
length protein is required.
The present work provides new insight into the processing
and function of CD44. The full-length protein is shown to be
imported from the cytoplasm to the nucleus by transportin1
where it induces gene transcription. Functional interaction
with transportin requires the membrane-proximal 20 amino
acids of the cytoplasmic tail of CD44 that contain the trans-
portin1-specific NLS. From the nucleus, full-length CD44
shuttles back to the cytoplasm upon Crm1 exportin binding.
This hitherto unrecognized mechanism of CD44 transloca-
tion can help uncover new molecular pathways whereby it
participates in the regulation of various cellular functions.
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